Kidney cancer trial aims to personalize treatment, reduce side effects
NCT ID NCT06860386
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 24 times
Summary
This study tests a new way of giving two approved drugs (pembrolizumab and axitinib) to people with advanced kidney cancer. Instead of a fixed schedule, the dose and timing are adjusted based on how well the tumor responds. The goal is to keep the cancer under control while possibly reducing side effects and the need for ongoing treatment. About 75 adults with clear cell kidney cancer that has spread will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.